264 related articles for article (PubMed ID: 35441435)
1. The effects of empagliflozin, dietary energy restriction, or both on appetite-regulatory gut peptides in individuals with type 2 diabetes and overweight or obesity: The SEESAW randomized, double-blind, placebo-controlled trial.
Sargeant JA; King JA; Yates T; Redman EL; Bodicoat DH; Chatterjee S; Edwardson CL; Gray LJ; Poulin B; Waheed G; Waller HL; Webb DR; Willis SA; Wilding JPH; Khunti K; Stensel DJ; Davies MJ
Diabetes Obes Metab; 2022 Aug; 24(8):1509-1521. PubMed ID: 35441435
[TBL] [Abstract][Full Text] [Related]
2. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY).
Yabe D; Shiki K; Homma G; Meinicke T; Ogura Y; Seino Y;
Diabetes Obes Metab; 2023 Dec; 25(12):3538-3548. PubMed ID: 37622398
[TBL] [Abstract][Full Text] [Related]
4. Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
Mordi NA; Mordi IR; Singh JS; McCrimmon RJ; Struthers AD; Lang CC
Circulation; 2020 Nov; 142(18):1713-1724. PubMed ID: 32865004
[TBL] [Abstract][Full Text] [Related]
5. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
[TBL] [Abstract][Full Text] [Related]
6. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
7. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
8. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.
Yabe D; Shiki K; Suzaki K; Meinicke T; Kotobuki Y; Nishida K; Clark D; Yasui A; Seino Y
BMJ Open; 2021 Apr; 11(4):e045844. PubMed ID: 33827843
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.
van Ruiten CC; Veltman DJ; Wijdeveld M; Ten Kulve JS; Kramer MHH; Nieuwdorp M; IJzerman RG
Diabetes Obes Metab; 2022 Aug; 24(8):1588-1597. PubMed ID: 35491524
[TBL] [Abstract][Full Text] [Related]
12. The effect of meal frequency in a reduced-energy regimen on the gastrointestinal and appetite hormones in patients with type 2 diabetes: A randomised crossover study.
Belinova L; Kahleova H; Malinska H; Topolcan O; Windrichova J; Oliyarnyk O; Kazdova L; Hill M; Pelikanova T
PLoS One; 2017; 12(4):e0174820. PubMed ID: 28369078
[TBL] [Abstract][Full Text] [Related]
13. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Sivalingam S; Wasehuus VS; Rotbain Curovic V; Blond MB; Hansen TW; Persson F; Rossing P
Diabetes Obes Metab; 2024 Jan; 26(1):54-64. PubMed ID: 37722966
[TBL] [Abstract][Full Text] [Related]
14. Gastric bypass surgery restores meal stimulation of the anorexigenic gut hormones glucagon-like peptide-1 and peptide YY independently of caloric restriction.
Evans S; Pamuklar Z; Rosko J; Mahaney P; Jiang N; Park C; Torquati A
Surg Endosc; 2012 Apr; 26(4):1086-94. PubMed ID: 22044971
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Tanaka A; Shimabukuro M; Okada Y; Taguchi I; Yamaoka-Tojo M; Tomiyama H; Teragawa H; Sugiyama S; Yoshida H; Sato Y; Kawaguchi A; Ikehara Y; Machii N; Maruhashi T; Shima KR; Takamura T; Matsuzawa Y; Kimura K; Sakuma M; Oyama JI; Inoue T; Higashi Y; Ueda S; Node K;
Cardiovasc Diabetol; 2017 Apr; 16(1):48. PubMed ID: 28403850
[TBL] [Abstract][Full Text] [Related]
16. Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adults.
Parnell JA; Reimer RA
Am J Clin Nutr; 2009 Jun; 89(6):1751-9. PubMed ID: 19386741
[TBL] [Abstract][Full Text] [Related]
17. Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus.
Kinduryte Schorling O; Clark D; Zwiener I; Kaspers S; Lee J; Iliev H
Adv Ther; 2020 Aug; 37(8):3463-3484. PubMed ID: 32372290
[TBL] [Abstract][Full Text] [Related]
18. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
van Can J; Sloth B; Jensen CB; Flint A; Blaak EE; Saris WH
Int J Obes (Lond); 2014 Jun; 38(6):784-93. PubMed ID: 23999198
[TBL] [Abstract][Full Text] [Related]
19. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
[TBL] [Abstract][Full Text] [Related]
20. Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial.
Shimizu W; Kubota Y; Hoshika Y; Mozawa K; Tara S; Tokita Y; Yodogawa K; Iwasaki YK; Yamamoto T; Takano H; Tsukada Y; Asai K; Miyamoto M; Miyauchi Y; Kodani E; Ishikawa M; Maruyama M; Ogano M; Tanabe J;
Cardiovasc Diabetol; 2020 Sep; 19(1):148. PubMed ID: 32977831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]